BioPharma News - MedCity News https://medcitynews.com/category/channel/biopharma/ Healthcare technology news, life science current events Thu, 28 Sep 2023 01:33:46 +0000 en-US hourly 1 https://wordpress.org/?v=6.3.1 https://medcitynews.com/uploads/2021/03/cropped-mblue-32x32.png BioPharma News - MedCity News https://medcitynews.com/category/channel/biopharma/ 32 32 40682243 Brainstorm’s ALS Data Fail to Persuade FDA Advisors, Who Vote Down the Stem Cell Therapy https://medcitynews.com/2023/09/fda-advisory-committee-brainstorm-cell-therapeutics-als-stem-cell-therapy/ https://medcitynews.com/2023/09/fda-advisory-committee-brainstorm-cell-therapeutics-als-stem-cell-therapy/#respond Thu, 28 Sep 2023 01:33:46 +0000 https://medcitynews.com/?p=650064

NurOwn, Brainstorm Cell Therapeutics’ experimental stem cell therapy for ALS, did not win the backing of an independent panel of FDA advisors. Many advisory committee members said they want to see more data from another clinical trial, the same guidance the FDA has given the biotech for nearly three years.

]]>
https://medcitynews.com/2023/09/fda-advisory-committee-brainstorm-cell-therapeutics-als-stem-cell-therapy/feed/ 0 650064
Ionis Posts Trial Data in Rare Disease That Position It to Finally Set Out on Its Own https://medcitynews.com/2023/09/ionis-posts-trial-data-in-rare-disease-that-position-it-to-finally-set-out-on-its-own/ https://medcitynews.com/2023/09/ionis-posts-trial-data-in-rare-disease-that-position-it-to-finally-set-out-on-its-own/#respond Tue, 26 Sep 2023 22:43:17 +0000 https://medcitynews.com/?p=649965 mRNA

Ionis Pharmaceuticals’ olezarsen has Phase 3 results showing the therapy handily beat a placebo at reducing fat levels in the blood due to a rare, inherited metabolic disorder with no FDA-approved drugs. Ionis plans early 2024 submissions for what could become the first medicine it commercializes without a partner.

]]>
https://medcitynews.com/2023/09/ionis-posts-trial-data-in-rare-disease-that-position-it-to-finally-set-out-on-its-own/feed/ 0 649965
After NASH Hopes Are Dashed, Intercept Pharma Agrees to $794M Buyout https://medcitynews.com/2023/09/after-nash-hopes-are-dashed-intercept-pharma-agrees-to-794m-buyout/ https://medcitynews.com/2023/09/after-nash-hopes-are-dashed-intercept-pharma-agrees-to-794m-buyout/#respond Tue, 26 Sep 2023 17:22:56 +0000 https://medcitynews.com/?p=649905

Intercept Pharmaceuticals’ acquisition by Alfasigma comes three months after the FDA again rejected the biotech’s drug as a treatment for the fatty liver disease NASH. But Intercept still has rare liver disease assets, and Italy-based Alfasigma says acquiring the company will help it expand in gastroenterology and hepatology.

]]>
https://medcitynews.com/2023/09/after-nash-hopes-are-dashed-intercept-pharma-agrees-to-794m-buyout/feed/ 0 649905
Novo Nordisk Turns to Flagship’s Valo Health for AI-Driven Cardio Drug R&D https://medcitynews.com/2023/09/novo-nordisk-artificial-intelligence-cardiovascular-disease-drug-discovery-valo-health/ https://medcitynews.com/2023/09/novo-nordisk-artificial-intelligence-cardiovascular-disease-drug-discovery-valo-health/#respond Mon, 25 Sep 2023 22:21:01 +0000 https://medcitynews.com/?p=649791 Image of heart and circulatory system

Novo Nordisk is paying Valo Health $60 million up front to gain three preclinical cardiovascular disease programs. Milestone payments for those programs and others covered under the artificial intelligence drug discovery pact could reach up to $2.7 billion.

]]>
https://medcitynews.com/2023/09/novo-nordisk-artificial-intelligence-cardiovascular-disease-drug-discovery-valo-health/feed/ 0 649791
Contamination Risk Sparks a Recall of GSK, Scynexis Antifungal Drug https://medcitynews.com/2023/09/yeast-infection-antifungal-gsk-scynexis-drug-recall/ https://medcitynews.com/2023/09/yeast-infection-antifungal-gsk-scynexis-drug-recall/#respond Mon, 25 Sep 2023 17:23:45 +0000 https://medcitynews.com/?p=649743

Scynexis said no adverse events or contamination problems have been reported for Brexafemme, an antifungal approved for treating vaginal yeast infections. The biotech said the risk of cross-contamination stems from the processes of the small molecule’s third-party manufacturer.

]]>
https://medcitynews.com/2023/09/yeast-infection-antifungal-gsk-scynexis-drug-recall/feed/ 0 649743
Startup Syntax Bio Leverages CRISPR to Transform Cell Therapy Manufacturing https://medcitynews.com/2023/09/startup-syntax-bio-leverages-crispr-to-transform-cell-therapy-manufacturing/ https://medcitynews.com/2023/09/startup-syntax-bio-leverages-crispr-to-transform-cell-therapy-manufacturing/#respond Sun, 24 Sep 2023 18:00:24 +0000 https://medcitynews.com/?p=649683

Syntax Bio’s technology platform uses CRISPR to direct stem cells to become a desired cell type in a process that’s more scalable and less expensive than current methods. The startup is raising a Series A round of financing to further demonstrate the potential of its technology.

]]>
https://medcitynews.com/2023/09/startup-syntax-bio-leverages-crispr-to-transform-cell-therapy-manufacturing/feed/ 0 649683
How Genome Sequencing Can Broaden the Scope of Newborn Screening https://medcitynews.com/2023/09/genome-sequencing-newborn-screening-rare-disease-rti-international-unc/ https://medcitynews.com/2023/09/genome-sequencing-newborn-screening-rare-disease-rti-international-unc/#respond Fri, 22 Sep 2023 16:31:38 +0000 https://medcitynews.com/?p=649545

Standard newborn screening can detect dozens of inherited diseases, but genomics technology enables testing for hundreds of them. A North Carolina program evaluating the feasibility of bringing genomics to newborn screening is expanding with an initial goal of testing 5,000 babies in the next year.

]]>
https://medcitynews.com/2023/09/genome-sequencing-newborn-screening-rare-disease-rti-international-unc/feed/ 0 649545
RFID with Barcode Medication Systems: Boosting Hospital Efficiency and Cost Savings https://medcitynews.com/2023/09/rfid-with-barcode-medication-systems-boosting-hospital-efficiency-and-cost-savings/ https://medcitynews.com/2023/09/rfid-with-barcode-medication-systems-boosting-hospital-efficiency-and-cost-savings/#respond Thu, 21 Sep 2023 22:14:20 +0000 https://medcitynews.com/?p=646038

This article explores the benefits of implementing RFID in healthcare settings and how hospitals can gradually transition from barcode to RFID-enabled medication systems, leading to substantial cost savings and improved patient care.

]]>
https://medcitynews.com/2023/09/rfid-with-barcode-medication-systems-boosting-hospital-efficiency-and-cost-savings/feed/ 0 646038
Once a Blockbuster Prospect, Is Travere’s Kidney Drug on Track to Become a Bust? https://medcitynews.com/2023/09/chronic-kidney-disease-travere-therapeutics-filspari-clinical-trial/ https://medcitynews.com/2023/09/chronic-kidney-disease-travere-therapeutics-filspari-clinical-trial/#respond Thu, 21 Sep 2023 20:30:59 +0000 https://medcitynews.com/?p=649473 Urinary system, bladder, kidney

Seven months after Travere Therapeutics’ flagship drug received accelerated FDA approval in a rare kidney disease, the molecule has fallen short of the key goal of its confirmatory test. It’s the small molecule’s second Phase 3 failure this year.

]]>
https://medcitynews.com/2023/09/chronic-kidney-disease-travere-therapeutics-filspari-clinical-trial/feed/ 0 649473
Merck KGaA Expands in AI-Driven R&D With Two Drug Discovery Deals https://medcitynews.com/2023/09/merck-kgaa-expands-in-ai-driven-rd-with-two-drug-discovery-deals/ https://medcitynews.com/2023/09/merck-kgaa-expands-in-ai-driven-rd-with-two-drug-discovery-deals/#respond Thu, 21 Sep 2023 13:48:11 +0000 https://medcitynews.com/?p=649410 AI, machine learning

Specific targets were not disclosed, but Merck KGaA is betting the artificial intelligence technologies of Exscientia and BenevolentAI will discover into new drugs for cancer, neurology, and immunology.

]]>
https://medcitynews.com/2023/09/merck-kgaa-expands-in-ai-driven-rd-with-two-drug-discovery-deals/feed/ 0 649410
Generative AI: Revolutionizing Pharmaceutical Industry and Driving Precision Medicine With Innovation, Equity and Ethics https://medcitynews.com/2023/09/generative-ai-revolutionizing-pharmaceutical-industry-and-driving-precision-medicine-with-innovation-equity-and-ethics/ https://medcitynews.com/2023/09/generative-ai-revolutionizing-pharmaceutical-industry-and-driving-precision-medicine-with-innovation-equity-and-ethics/#respond Wed, 20 Sep 2023 20:23:04 +0000 https://medcitynews.com/?p=646026

With conscious and ethical use of Generative AI we can forge a future that is empathetic, innovative and can meet all our needs at the right time and place.

]]>
https://medcitynews.com/2023/09/generative-ai-revolutionizing-pharmaceutical-industry-and-driving-precision-medicine-with-innovation-equity-and-ethics/feed/ 0 646026
FDA Rejects ARS Pharma’s Nasal Spray Alternative to Injectable Epinephrine https://medcitynews.com/2023/09/fda-rejection-nasal-spray-epinephrine-epipen-alternative-ars-pharma/ https://medcitynews.com/2023/09/fda-rejection-nasal-spray-epinephrine-epipen-alternative-ars-pharma/#respond Wed, 20 Sep 2023 17:51:20 +0000 https://medcitynews.com/?p=649275 FDA sign, headquarters

ARS Pharmaceuticals frames its intranasal epinephrine spray as a needle-free alternative to products such as EpiPen. Though this spray won the backing of an FDA advisory committee, the agency is now requiring that ARS Pharma run another study to support a regulatory submission.

]]>
https://medcitynews.com/2023/09/fda-rejection-nasal-spray-epinephrine-epipen-alternative-ars-pharma/feed/ 0 649275
BeiGene, Novartis Drug Alliance Ends; It’s Their Second Terminated Deal This Year https://medcitynews.com/2023/09/beigene-novartis-drug-alliance-ends-its-their-second-terminated-deal-this-year/ https://medcitynews.com/2023/09/beigene-novartis-drug-alliance-ends-its-their-second-terminated-deal-this-year/#respond Tue, 19 Sep 2023 22:30:40 +0000 https://medcitynews.com/?p=649215

BeiGene welcomes the return of the immunotherapy’s rights as an opportunity to make it the backbone of its solid tumors strategy. But Novartis cedes an opportunity to gain a competitor to established cancer immunotherapies from Merck and Bristol Myers Squibb.

]]>
https://medcitynews.com/2023/09/beigene-novartis-drug-alliance-ends-its-their-second-terminated-deal-this-year/feed/ 0 649215
Startup Magnet Biomedicine Attracts $50M to Expand Scope of Molecular Glue Drugs https://medcitynews.com/2023/09/startup-magnet-biomedicine-attracts-50m-to-expand-scope-of-molecular-glue-drugs/ https://medcitynews.com/2023/09/startup-magnet-biomedicine-attracts-50m-to-expand-scope-of-molecular-glue-drugs/#respond Tue, 19 Sep 2023 14:11:41 +0000 https://medcitynews.com/?p=649041

Magnet Biomedicine builds on decades of molecular glue research from its scientific co-founder, Harvard University Professor Stuart Schreiber. The startup is developing drugs that take these glues beyond the biotech industry’s current focus on targeted protein degradation.

]]>
https://medcitynews.com/2023/09/startup-magnet-biomedicine-attracts-50m-to-expand-scope-of-molecular-glue-drugs/feed/ 0 649041
BioNTech and CEPI Team Up to Develop Mpox Vaccine That Meets 100-Day Goal https://medcitynews.com/2023/09/biontech-cepi-mpox-mrna-vaccine-infectious-disease/ https://medcitynews.com/2023/09/biontech-cepi-mpox-mrna-vaccine-infectious-disease/#respond Mon, 18 Sep 2023 20:29:36 +0000 https://medcitynews.com/?p=648969

The Coalition for Epidemic Preparedness Innovations, or CEPI, has pledged up to $90 million to BioNTech’s messenger RNA vaccine candidates for mpox. This research could help advance the scientific understanding of the application of mRNA technology to Orthopoxviruses, which includes mpox, formerly known as monkeypox.

]]>
https://medcitynews.com/2023/09/biontech-cepi-mpox-mrna-vaccine-infectious-disease/feed/ 0 648969
Data-Driven Diversity: Using Granular Insights to Design More Inclusive Trials https://medcitynews.com/2023/09/data-driven-diversity-using-granular-insights-to-design-more-inclusive-trials/ https://medcitynews.com/2023/09/data-driven-diversity-using-granular-insights-to-design-more-inclusive-trials/#respond Mon, 18 Sep 2023 19:30:16 +0000 https://medcitynews.com/?p=645354

The healthcare industry is sitting on a wealth of data gathered from electronic health records, commercial pharmacies, health systems and payers, and health tech companies. So much that it makes up one-third of the world’s data. Pharmaceutical companies need to tap into this type of data to build inclusive clinical trials,

]]>
https://medcitynews.com/2023/09/data-driven-diversity-using-granular-insights-to-design-more-inclusive-trials/feed/ 0 645354
FDA Approves GSK Myelofibrosis Med That Has Edge Over Others in Drug Class https://medcitynews.com/2023/09/fda-drug-approval-gsk-myelofibrosis-jak-inhibitor-ojjaara/ https://medcitynews.com/2023/09/fda-drug-approval-gsk-myelofibrosis-jak-inhibitor-ojjaara/#respond Sun, 17 Sep 2023 17:57:29 +0000 https://medcitynews.com/?p=648897

FDA approval of GSK’s Ojjaara in myelofibrosis introduces a new competitor to blockbuster Incyte drug Jakafi. Ojjaara was part of GSK’s $1.9 billion acquisition of Sierra Oncology last year.

]]>
https://medcitynews.com/2023/09/fda-drug-approval-gsk-myelofibrosis-jak-inhibitor-ojjaara/feed/ 0 648897
RayzeBio, Neumora Perk Up the IPO Market, Raising $561M for Clinical Trials https://medcitynews.com/2023/09/biotech-ipo-rayzebio-cancer-neumora-depression-clinical-trials/ https://medcitynews.com/2023/09/biotech-ipo-rayzebio-cancer-neumora-depression-clinical-trials/#respond Fri, 15 Sep 2023 18:45:16 +0000 https://medcitynews.com/?p=648729

RayzeBio’s IPO will support pivotal testing of a targeted radiopharmaceutical for cancer patients who progress after treatment with Novartis’s Lutathera. Neumora will apply its IPO cash toward Phase 3 testing of a depression drug with a novel mechanism of action.

]]>
https://medcitynews.com/2023/09/biotech-ipo-rayzebio-cancer-neumora-depression-clinical-trials/feed/ 0 648729
While Auto vs. Allo Cell Therapy Debate Continues, VCs Look for ‘Next Shiny Thing’ https://medcitynews.com/2023/09/while-auto-vs-allo-cell-therapy-debate-continues-vcs-look-for-next-shiny-thing/ https://medcitynews.com/2023/09/while-auto-vs-allo-cell-therapy-debate-continues-vcs-look-for-next-shiny-thing/#respond Thu, 14 Sep 2023 23:53:04 +0000 https://medcitynews.com/?p=648651 T-cells attacking cancer cell illustration of microscopic photosT-cells attacking cancer cell illustration of microscopic photos

Allogeneic cell therapy hasn’t caught up to autologous cell therapy yet, and the disappointing data so far has soured the entire allogeneic field for at least one venture capitalist. The cell therapy debate was one of the topics covered during a panel discussion at the Biopharm America conference.

]]>
https://medcitynews.com/2023/09/while-auto-vs-allo-cell-therapy-debate-continues-vcs-look-for-next-shiny-thing/feed/ 0 648651
What CVS Stands to Gain by Setting Up Biosimilar Subsidiary Cordavis https://medcitynews.com/2023/09/what-cvs-stands-to-gain-by-setting-up-biosimilar-subsidiary-cordavis/ https://medcitynews.com/2023/09/what-cvs-stands-to-gain-by-setting-up-biosimilar-subsidiary-cordavis/#respond Thu, 14 Sep 2023 01:11:52 +0000 https://medcitynews.com/?p=648555

Pharmaceutical industry observers say CVS Health’s creation of Cordavis, a new biosimilar drugs company, is part of a strategy to make its move into this market as profitable as possible.

]]>
https://medcitynews.com/2023/09/what-cvs-stands-to-gain-by-setting-up-biosimilar-subsidiary-cordavis/feed/ 0 648555
An Ounce of Prevention Isn’t Enough To Treat Obesity https://medcitynews.com/2023/09/an-ounce-of-prevention-isnt-enough-to-treat-obesity/ https://medcitynews.com/2023/09/an-ounce-of-prevention-isnt-enough-to-treat-obesity/#respond Wed, 13 Sep 2023 00:20:42 +0000 https://medcitynews.com/?p=644898

If we want to support people with obesity, the weight loss debate must stop conflating obesity prevention with obesity treatment. Instead, we should focus on the tools that best solve the needs of people where they are – just as we would for cancer or diabetes – by making the most effective treatments possible available.

]]>
https://medcitynews.com/2023/09/an-ounce-of-prevention-isnt-enough-to-treat-obesity/feed/ 0 644898
Neuro Startup Arialys Raises $58M for Privilege of Tackling Brain Inflammation https://medcitynews.com/2023/09/brain-inflammation-startup-rare-disease-astellas-arialys/ https://medcitynews.com/2023/09/brain-inflammation-startup-rare-disease-astellas-arialys/#respond Tue, 12 Sep 2023 21:28:52 +0000 https://medcitynews.com/?p=648363

Avalon BioVentures unveiled new portfolio company Arialys Therapeutics. The startup’s lead program, an antibody from Astellas Pharma, is a potential treatment for anti-NMDA receptor encephalitis (ANRE), a rare autoimmune inflammatory disorder.

]]>
https://medcitynews.com/2023/09/brain-inflammation-startup-rare-disease-astellas-arialys/feed/ 0 648363
FDA Approves Updated Covid-19 Vaccines to Address Now Circulating Variants https://medcitynews.com/2023/09/fda-approves-updated-covid-19-vaccines-to-address-now-circulating-variants/ https://medcitynews.com/2023/09/fda-approves-updated-covid-19-vaccines-to-address-now-circulating-variants/#respond Mon, 11 Sep 2023 22:10:30 +0000 https://medcitynews.com/?p=648240

The FDA said the updated messenger RNA vaccines from Pfizer/BioNTech and Moderna will protect against the omicron subvariants now prevalent in circulation. Left out of the FDA decision is Novavax, whose protein-based vaccine is still under regulatory review.

]]>
https://medcitynews.com/2023/09/fda-approves-updated-covid-19-vaccines-to-address-now-circulating-variants/feed/ 0 648240
Moderna Puts Up $120M to Start Cancer Drug R&D Alliance With Immatics https://medcitynews.com/2023/09/moderna-puts-up-120m-to-start-cancer-drug-rd-alliance-with-immatics/ https://medcitynews.com/2023/09/moderna-puts-up-120m-to-start-cancer-drug-rd-alliance-with-immatics/#respond Mon, 11 Sep 2023 16:48:09 +0000 https://medcitynews.com/?p=648156

Moderna and Immatics aim to see if the combination of their respective technologies can lead to better cancer treatments spanning multiple therapeutic modalities. Milestone payments to immunotherapy developer Immatics could top $1.7 billion.

]]>
https://medcitynews.com/2023/09/moderna-puts-up-120m-to-start-cancer-drug-rd-alliance-with-immatics/feed/ 0 648156
Click Expands to Substance Use Disorder With Indivior Digital Therapeutics Pact https://medcitynews.com/2023/09/digital-therapeutic-substance-use-disorder-indivior-click-therapeutics/ https://medcitynews.com/2023/09/digital-therapeutic-substance-use-disorder-indivior-click-therapeutics/#respond Sun, 10 Sep 2023 12:36:14 +0000 https://medcitynews.com/?p=648099

Digital therapeutics developer Click Therapeutics is partnering with Indivior to develop a mobile app for substance use disorder. Indivior is now Click’s third development partner, following deals with Boehringer Ingelheim and Otsuka Pharmaceutical.

]]>
https://medcitynews.com/2023/09/digital-therapeutic-substance-use-disorder-indivior-click-therapeutics/feed/ 0 648099
Seagen and Nurix Join Forces to Develop a New Class of Cancer Medicines https://medcitynews.com/2023/09/seagen-nurix-cancer-antibody-drug-conjugate-protein-degrader/ https://medcitynews.com/2023/09/seagen-nurix-cancer-antibody-drug-conjugate-protein-degrader/#respond Thu, 07 Sep 2023 23:44:05 +0000 https://medcitynews.com/?p=648003

Seagen and Nurix are bringing their respective technologies together to develop a new class of cancer drugs called degrader antibody conjugates. Nurix CEO Arthur Sands says the multi-year, multi-target collaboration expands the reach of each company’s technology.

]]>
https://medcitynews.com/2023/09/seagen-nurix-cancer-antibody-drug-conjugate-protein-degrader/feed/ 0 648003
Recursion Vets Unveil Startup Noetik, Using AI to Unlock Tumor Biology https://medcitynews.com/2023/09/recursion-vets-unveil-startup-noetik-using-ai-to-unlock-tumor-biology/ https://medcitynews.com/2023/09/recursion-vets-unveil-startup-noetik-using-ai-to-unlock-tumor-biology/#respond Thu, 07 Sep 2023 19:24:18 +0000 https://medcitynews.com/?p=647919

By revealing how tumors interact with immune cells, Noetik aims to identify new targets for new cancer drugs. The startup and its artificial intelligence-driven platform are supported by $14 million in seed financing.

]]>
https://medcitynews.com/2023/09/recursion-vets-unveil-startup-noetik-using-ai-to-unlock-tumor-biology/feed/ 0 647919
Orphan Drug Development Is Next for Tech to Tackle https://medcitynews.com/2023/09/orphan-drug-development-is-next-for-tech-to-tackle/ https://medcitynews.com/2023/09/orphan-drug-development-is-next-for-tech-to-tackle/#respond Wed, 06 Sep 2023 22:16:13 +0000 https://medcitynews.com/?p=644700

Drug developers need policies and technological infrastructure to execute on their goal of being patient-focused. At a minimum, this means a compliant way to engage patients and truly hear their voices; at its most effective, patient engagement also meets patients where they are – whenever and wherever that may be.

]]>
https://medcitynews.com/2023/09/orphan-drug-development-is-next-for-tech-to-tackle/feed/ 0 644700
A One-Time Treatment for NASH? Kriya Strikes Deal for Liver Disease Gene Therapy https://medcitynews.com/2023/09/fatty-liver-disease-nash-gene-therapy-kriya-acquisition/ https://medcitynews.com/2023/09/fatty-liver-disease-nash-gene-therapy-kriya-acquisition/#respond Wed, 06 Sep 2023 17:23:11 +0000 https://medcitynews.com/?p=647787

Gene therapy biotech Kriya Therapeutics has acquired Tramontane Therapeutics, a startup focused on metabolic diseases. Tramontane brings a gene therapy that’s a potential one-time treatment for the fatty liver disease NASH.

]]>
https://medcitynews.com/2023/09/fatty-liver-disease-nash-gene-therapy-kriya-acquisition/feed/ 0 647787
Nestlé Sells Peanut Allergy Drug, Ending the Food Giant’s Foray Into Biotech https://medcitynews.com/2023/09/nestle-peanut-allergy-drug-palforzia-stallergenes-greer/ https://medcitynews.com/2023/09/nestle-peanut-allergy-drug-palforzia-stallergenes-greer/#respond Tue, 05 Sep 2023 23:06:06 +0000 https://medcitynews.com/?p=647667

Peanut allergy therapy Palforzia, which Nestlé acquired in a multi-billion dollar deal, has been sold to allergy product company Stallergenes Greer. Palforzia was the first FDA-approved drug for peanut allergy, but its sales were hampered by the Covid-19 pandemic.

]]>
https://medcitynews.com/2023/09/nestle-peanut-allergy-drug-palforzia-stallergenes-greer/feed/ 0 647667